Hemab Therapeutics Holdings, Inc. Common Stock (COAG) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T22:31:25.007Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:31:25.007Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 28.37
Unrounded diluted TTM EPS · period ending 2026-06-30: N/A

FMP input reference: de430a97f2ce1d56e5593aeaf7513a4829955f1ae9df1fe435740c279e59bff8

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

COAG PE Ratio Metrics

PE RATIO

N/A

COAG Competitors' PE Ratio

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

Current

Market Cap

$1.33B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OMER

Omeros Corporation

vs COAG

Market Cap

$1.34B

PE Ratio

10.76

TTM Avg

10.02

3Y Avg

9.28

5Y Avg

5.37

DRTS

Alpha Tau Medical Ltd

vs COAG

Market Cap

$1.31B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INBX

Inhibrx Biosciences Inc.

vs COAG

Market Cap

$1.37B

PE Ratio

N/A

TTM Avg

0.13

3Y Avg

0.13

5Y Avg

0.13

PNTG

The Pennant Group, Inc.

vs COAG

Market Cap

$1.39B

PE Ratio

44.39

TTM Avg

39.73

3Y Avg

39.80

5Y Avg

78.59

BRVE

Braveheart Bio, Inc.

vs COAG

Market Cap

$1.40B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRA

Kailera Therapeutics, Inc.

vs COAG

Market Cap

$1.40B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TSHA

Taysha Gene Therapies, Inc.

vs COAG

Market Cap

$1.40B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORIC

ORIC Pharmaceuticals, Inc.

vs COAG

Market Cap

$1.24B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OMDA

Omada Health

vs COAG

Market Cap

$1.23B

PE Ratio

329.05

TTM Avg

351.15

3Y Avg

351.15

5Y Avg

351.15

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)	$1.33B	N/A	N/A	N/A	N/A
Omeros Corporation (OMER)vs ›	$1.34B	10.76	10.02	9.28	5.37
Alpha Tau Medical Ltd (DRTS)vs ›	$1.31B	N/A	N/A	N/A	N/A
Inhibrx Biosciences Inc. (INBX)vs ›	$1.37B	N/A	0.13	0.13	0.13
The Pennant Group, Inc. (PNTG)vs ›	$1.39B	44.39	39.73	39.80	78.59
Braveheart Bio, Inc. (BRVE)vs ›	$1.40B	N/A	N/A	N/A	N/A
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.40B	N/A	N/A	N/A	N/A
Taysha Gene Therapies, Inc. (TSHA)vs ›	$1.40B	N/A	N/A	N/A	N/A
ORIC Pharmaceuticals, Inc. (ORIC)vs ›	$1.24B	N/A	N/A	N/A	N/A
Omada Health (OMDA)vs ›	$1.23B	329.05	351.15	351.15	351.15

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$28.37

÷

Forward EPS (Est.)

$-3.10

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

COAG PE Ratio Metrics

COAG Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics